

	<i>BRCA</i> mutation (n=91)	<i>BRCA</i> wild-type (n=171)
Secondary CRS (n=80, %)	<p><b>24</b></p> <p>BEV 2 PARPi 10 Maintenance</p>	<p><b>56</b></p> <p>BEV 20 PARPi 2 Maintenance</p>
No surgery (n=182, %)	<p><b>67</b></p> <p>BEV 14 PARPi 24 Maintenance</p>	<p><b>115</b></p> <p>BEV 54 PARPi 3 Maintenance</p>

**S2 Fig.** Composition of the study population by *BRCA1/2* mutational status, secondary CRS, and maintenance therapy. BEV, bevacizumab; CRS, cytoreductive surgery; PARPi, poly(ADP-ribose) polymerase inhibitor.